Jaktinib for the Treatment of Ruxolitinib Intolerance of Myelofibrosis

Clinical trial NCT04217993 · COMPLETED

Trial details

NCT number: NCT04217993
Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Primary Myelofibrosis (PMF)Post-polycythemia Vera Myelofibrosis(Post-PV MF)Post-essential Thrombocythemia Myelofibrosis(Post-ET MF)

Start date: 2020-01-07
Primary completion: 2022-08-03
Enrollment: 51

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.